Calculating Glucagon‐Like Pepide‐1 Receptor Agonist‐Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System

Key Points

• This research aims to assess the risk of medullary thyroid cancer (MTC) linked to GLP-1 receptor agonists (GLP-1RAs).
• Integrated data from the Surveillance, Epidemiology and End Results Cancer Registry and FDA Adverse Event Reporting System.
• Compared risk of MTC between GLP-1RAs and other drug classes.
• GLP-1RAs demonstrated a higher risk prediction for medullary thyroid cancer compared to other medications.
• Findings suggest necessitating further prospective studies for validation.